Samsung Biologics announced on the 17th that it has signed a contract for contract manufacturing organization (CMO) with a U.S. pharmaceutical company.
The contract size is 111.2 billion won, which corresponds to 3.01% of the consolidated revenue from the previous year. The contract period is until Oct. 2, 2030.
The opposing corporations will be disclosed upon the contract's expiration date to maintain business confidentiality. Last month, Samsung Biologics secured a CMO contract worth 900 billion won with a European pharmaceutical company.